ClinicaliQ Trial Snapshot
- ADH1 and ADH2 Disease Monitoring Study (DMS) — Active Not Recruiting • NCT05227287.
- Study tracking how autosomal dominant hypocalcaemia types 1 and 2 develop and progress over time using patient medical records.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection. Conditions: Autosomal Dominant Hypocalcemia Lead Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company Planned Enrollment: 95 participants